Roche's emicizumab haemophilia drug succeeds in trial
ZURICH, Dec (Shanghai: 600875.SS - news) 22 (Reuters) - Roche Holding AG (IOB: 0QOK.IL - news) 's emicizumab drug for treating haemophilia A met its primary endpoint in a phase III study, the Swiss drugmaker said on Thursday.
"The study showed a statistically significant reduction in the number of bleeds over time in people treated with emicizumab prophylaxis compared to those receiving no prophylactic treatment," it said in a statement, adding all secondary endpoints were also met.
Roche is hoping to win a slice of the $11 billion-a-year haemophilia drug market with the drug, also known as ACE910, which represents a threat to more traditional treatments from Novo Nordisk (LSE: 0QIU.L - news) and Shire (Xetra: S7E.DE - news) . (Reporting by Michael Shields)